Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents
Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide affecting a third of adults and 12% of children in Western countries. In around 50–60%% of cases, NAFLD and type 2 diabetes mellitus (T2DM) coexist and act synergistically to increase the r...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-07-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S166526812200093X |
| _version_ | 1827915211675271168 |
|---|---|
| author | Diego García-Compeán Ramesh Kumar Ángel Noe del Cueto-Aguilera Héctor Jesús Maldonado-Garza Jesús Zacarías Villarreal-Pérez |
| author_facet | Diego García-Compeán Ramesh Kumar Ángel Noe del Cueto-Aguilera Héctor Jesús Maldonado-Garza Jesús Zacarías Villarreal-Pérez |
| author_sort | Diego García-Compeán |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide affecting a third of adults and 12% of children in Western countries. In around 50–60%% of cases, NAFLD and type 2 diabetes mellitus (T2DM) coexist and act synergistically to increase the risk of adverse hepatic and extra-hepatic outcomes. T2DM is a strong risk factor for rapid progression of NAFLD to nonalcoholic steatohepatitis (NASH), cirrhosis or hepatocellular carcinoma (HCC), which have become frequent indications of liver transplantation.The pathophysiology of NAFLD is complex and its relationship with T2DM is bidirectional, where lipotoxicity and insulin resistance (IR), act as the strongest pillars.To date, no pharmacological treatment has been approved for NAFLD. However, there is an intense research with numerous drugs focused on reversing inflammation and liver fibrosis through modulation of molecular targets without good results.It has been known for some time that weight reduction >10% is associated to histological improvement of NAFLD. Recently, glycemic control has been shown to induce similar results. Diet and physical exercise for weight reduction have limitations, so alternative methods (pharmacologic, endoscopic or surgical) may be required. Currently, new antidiabetic drugs inducing weight loss, have been recently approved for the treatment of obesity. Nevertheless, their therapeutic effects on NAFLD have not been extensively studied.We will review here, recently published data on the effects of weight loss and glycemic control on the histological and metabolic parameters of NAFLD and recent published data on therapeutic studies of NAFLD with new antidiabetic drugs. |
| first_indexed | 2024-03-13T02:56:17Z |
| format | Article |
| id | doaj.art-25f395ee64834d92bb07f6c1dceab18b |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-03-13T02:56:17Z |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-25f395ee64834d92bb07f6c1dceab18b2023-06-28T04:29:12ZengElsevierAnnals of Hepatology1665-26812023-07-01284100751Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agentsDiego García-Compeán0Ramesh Kumar1Ángel Noe del Cueto-Aguilera2Héctor Jesús Maldonado-Garza3Jesús Zacarías Villarreal-Pérez4Gastroenterology Service and Internal Medicine Department, Faculty of Medicine, University Hospital ''Dr. José E. González”, Universidad Autónoma de Nuevo León, Monterrey 64700, Nuevo León, Mexico; Corresponding author.Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, IndiaGastroenterology Service and Internal Medicine Department, Faculty of Medicine, University Hospital ''Dr. José E. González”, Universidad Autónoma de Nuevo León, Monterrey 64700, Nuevo León, MexicoGastroenterology Service and Internal Medicine Department, Faculty of Medicine, University Hospital ''Dr. José E. González”, Universidad Autónoma de Nuevo León, Monterrey 64700, Nuevo León, MexicoEndocrinology Service and Internal Medicine Department, University Hospital. Autonomous University of Nuevo León, México. Madero y Gonzalitos Colonia Mitras CP 64700 Monterrey Nuevo León, México., Monterrey 64700, MexicoNonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide affecting a third of adults and 12% of children in Western countries. In around 50–60%% of cases, NAFLD and type 2 diabetes mellitus (T2DM) coexist and act synergistically to increase the risk of adverse hepatic and extra-hepatic outcomes. T2DM is a strong risk factor for rapid progression of NAFLD to nonalcoholic steatohepatitis (NASH), cirrhosis or hepatocellular carcinoma (HCC), which have become frequent indications of liver transplantation.The pathophysiology of NAFLD is complex and its relationship with T2DM is bidirectional, where lipotoxicity and insulin resistance (IR), act as the strongest pillars.To date, no pharmacological treatment has been approved for NAFLD. However, there is an intense research with numerous drugs focused on reversing inflammation and liver fibrosis through modulation of molecular targets without good results.It has been known for some time that weight reduction >10% is associated to histological improvement of NAFLD. Recently, glycemic control has been shown to induce similar results. Diet and physical exercise for weight reduction have limitations, so alternative methods (pharmacologic, endoscopic or surgical) may be required. Currently, new antidiabetic drugs inducing weight loss, have been recently approved for the treatment of obesity. Nevertheless, their therapeutic effects on NAFLD have not been extensively studied.We will review here, recently published data on the effects of weight loss and glycemic control on the histological and metabolic parameters of NAFLD and recent published data on therapeutic studies of NAFLD with new antidiabetic drugs.http://www.sciencedirect.com/science/article/pii/S166526812200093XNASHInsulin resistanceGlycemic controlGLP-1R agonistsSGLT2 inhibitors |
| spellingShingle | Diego García-Compeán Ramesh Kumar Ángel Noe del Cueto-Aguilera Héctor Jesús Maldonado-Garza Jesús Zacarías Villarreal-Pérez Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents Annals of Hepatology NASH Insulin resistance Glycemic control GLP-1R agonists SGLT2 inhibitors |
| title | Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents |
| title_full | Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents |
| title_fullStr | Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents |
| title_full_unstemmed | Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents |
| title_short | Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents |
| title_sort | body weight loss and glycemic control on the outcomes of patients with nafld the role of new antidiabetic agents |
| topic | NASH Insulin resistance Glycemic control GLP-1R agonists SGLT2 inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S166526812200093X |
| work_keys_str_mv | AT diegogarciacompean bodyweightlossandglycemiccontrolontheoutcomesofpatientswithnafldtheroleofnewantidiabeticagents AT rameshkumar bodyweightlossandglycemiccontrolontheoutcomesofpatientswithnafldtheroleofnewantidiabeticagents AT angelnoedelcuetoaguilera bodyweightlossandglycemiccontrolontheoutcomesofpatientswithnafldtheroleofnewantidiabeticagents AT hectorjesusmaldonadogarza bodyweightlossandglycemiccontrolontheoutcomesofpatientswithnafldtheroleofnewantidiabeticagents AT jesuszacariasvillarrealperez bodyweightlossandglycemiccontrolontheoutcomesofpatientswithnafldtheroleofnewantidiabeticagents |